Triall partners with Crucial Data Solutions to realize the


MAARSSEN, The Netherlands, March 24, 2022 (GLOBE NEWSWIRE) — Triall, a tokenized platform for blockchain-based clinical trial technology, has partnered with Crucial Data Solutions (CDS), an eClinical software provider that offers a range of specialized applications for clinical trials collection and management of trial data. Over the past decade, CDS has been a recognized innovator and industry leader in eClinical software, having implemented its eClinical solutions in more than 7,000 clinical trials worldwide.

As part of this partnership, Triall will integrate its blockchain APIs with CDS’s eClinical solutions, realizing the world’s first end-to-end platform of blockchain-powered eClinical solutions. The platform covers all essential clinical trial functions to radically advance data integrity, auditability and interoperability in the global clinical trial industry.

This historic partnership is a big step forward for Triall, as it enables the company to innovate based on a validated eClinical platform trusted by thousands of industry professionals worldwide. Offered as part of the Triall ecosystem, eClinical solutions will apply blockchain to generate verifiable proof of the integrity of clinical trial data, documents and processes. Additionally, Triall leverages decentralized identity technologies and self-sovereign identity (SSI) standards to facilitate interoperability between systems and clinical trial activities.

The Triall-CDS partnership is fully focused on delivering a scalable platform that adapts to emerging trends in the clinical trial industry, including real-world data collection and trial designs decentralized, while maximizing efficiency and reliability.

The partnership also has wild implications for the Triall TRL platform’s native utility token, which is gaining in utility as Triall’s software stack expands. TRL is used to pay for all software offered in the Triall ecosystem and was launched last year after a successful crowdfunding campaign that raised $2.4 million from over 1,500 investors. Prior to its token launch, Triall developed and commercialized its Verial eTMF blockchain-integrated document management system, which marked the world’s first implementation of blockchain in ongoing and ongoing clinical trials.

“CDS and Triall share a common vision that patients and clinical research sponsors expect and deserve improved data privacy, security and accountability. This partnership advances the future by giving patients unprecedented confidence in knowing that their data is secure and their privacy is protected. protected.” – Jeff Rogers, president of Crucial Data Solutions

“Clinical trials have become increasingly digital, data-driven and decentralized. This underscores the need for an end-to-end eClinical platform that unifies and secures all essential trial activities and processes. We have found the perfect partner in CDS and are very excited to continue our journey together.” – Hadil Es-Sbai, CEO of Triall

About Trial
Triall brings Web3 to medical research by creating a digital ecosystem of blockchain-integrated software solutions that secure and streamline clinical trials. Triall’s solutions make clinical trials tamper-proof and enable secure and efficient integrations between the many isolated systems and parties involved in clinical trial processes. Triall’s software is co-created with clinical trial professionals to ensure the best user experience, solving real industry problems.

For any request, contact [email protected]

Visit the website:

About Crucial Data Solutions
Founded in 2010, Crucial Data Solutions (CDS) provides the most innovative low-code/no-code clinical trial and data management technology on the market today. TrialKit, our cloud-based platform available through a native web and mobile app, enables end-to-end clinical trial management for medical devices, diagnostics, digital therapeutics, and biotechnology companies of all sizes. Design and deploy validated studies in days, not weeks, using our intuitive study builder that requires no programming. Over 10,000 global users have leveraged TrialKit’s flexibility to deploy over 7,000 studies through all phases of development, including Verily (an Alphabet subsidiary), ICON GPHS, FUEL Studios, Catalyst Clinical Research, SISCAPA Assay Technologies, CDx Diagnostics and Optinose, and many more.

Visit the website:

Related images

Picture 1

This content was posted through the press release distribution service on

  • Featured image for Triall


About Author

Comments are closed.